|
Pathogenesys LLC was founded in 2003 for the purpose of offering Pathology services to the Pharmaceutical and Biotechnology industries. Success in this competitive field is dependent upon the quality of service but also on fulfilling the unmet needs in drug development. This niche-focus requires novel assays or technologies to remain ahead of competition or for discovery of important biomarkers. To this end, Pathogenesys incentivises it employees to discovery intellectual properties that will add value to the company. Wherever practical, Pathogenesys will protect and license commercially viable technologies. Pathogenesys is also interested in development of business to business relationships to partner in the commercialization of key intellectual properties. For more specific information about proprietary technologies available or under development, see the Proprietary Technologies page in this web site.
Pathogenesys is currently seeking angel or venture investment for a partnership to commercialize a viable new technology for the analysis of live cells in high-throughput format. The immediate applications for this technology include chemoresistance testing and drug discovery.
Pathogenesys is also currently looking for partners or investors to help with the ongoing clinical validation of the Serum DNA assay. Significant contributors would be in line to become stake holders in the intellectual property.
|
